Hugel Aesthetics began as a bold vision to democratize the world of medical aesthetics. Born from a strategic joint venture between South Korean industry leader Hugel, Inc. and Austrian pharmaceutical expert Croma-Pharma GmbH in 2018, the company set out to bridge the gap between premium quality and accessibility. What started as a mission to bring K-Beauty's renowned innovation to the Western world has evolved into a dynamic global force, challenging the status quo of the aesthetics industry.
Headquartered in Newport Beach, California, Hugel Aesthetics has rapidly expanded its footprint across North America and Australia. The company's journey is defined by a commitment to 'sparking joy' in every beauty journey, believing that high-quality aesthetic treatments should be attainable for everyone, not just a privileged few. By leveraging proprietary technologies and a consumer-centric approach, Hugel Aesthetics has successfully introduced a portfolio of top-tier injectables, including the botulinum toxin Letybo, to new markets. Today, the company stands at the intersection of beauty and technology, continually striving to empower individuals to embrace their unique aesthetic aspirations with confidence and ease.
Canada only
United States